Treace Medical Concepts(NASDAQ) TMCI

Treace Medical Concepts, Inc. helps doctors fix foot deformities. Its tools help surgeons repair bones in three dimensions. This helps patients walk sooner after their surgery.

Fixing More Than Just Bunions

• Lapiplasty System: Flagship 3D correction system designed to fix the root cause of bunions by securing unstable joints.
• Minimally Invasive Systems: Nanoplasty and Percuplasty tools used for smaller surgical cuts during bunion repair.
• Midfoot Correction: Adductoplasty System used for fixing midfoot arthritis and related bone deformities.
• Implant Platforms: SpeedMTP and SpeedPlate systems provide compression for bone fusions in the foot and ankle.
• Digital Planning: IntelliGuide technology creates 3D-printed cut guides based on the specific foot anatomy of each patient.

Defending Tech and Adding Tools

• Introduced the Nanoplasty and Percuplasty 3D systems to address the growing market for minimally invasive surgery.
• Launched the SpeedTMT Rapid Compression Implant to provide surgeons with more options for foot bone fusions.
• Initiated a patent infringement lawsuit against Stryker in Oct. 2024 to protect its core 3D correction technology.
• Filed a separate legal action against Zimmer Biomet and Paragon 28 in May 2025 regarding its Lapiplasty patents.

How Treace Wins the Market

Treace maintains a portfolio of 101 granted U.S. patents and 45 worldwide patents to protect its proprietary surgical methods as of June 30, 2026. The company uses a direct sales force and independent agencies to sell its products to hospitals and surgery centers across the United States.

A Look at the Ledger

• Revenue was $45.4 million for the three-month period ended June 30, 2026, down 4.2% year over year.
• Gross margin reached 78.5% for the quarter ended June 30, 2026, compared to 79.7% in the same period of 2025.
• Net loss was $33.8 million for the six-month period ended June 30, 2026.
• The company held $12.6 million in cash and $33.0 million in marketable securities as of June 30, 2026.
• Market capitalization was $284.1 million based on recent trading data.

Bottom Line

Treace has transitioned from a single-product company into a broader provider of foot and ankle surgical solutions. It continues to defend its intellectual property while expanding its reach into minimally invasive and midfoot procedures.